Purpose
Why these data are shared
The situation
Dan has a grade 4 IDH-mutant astrocytoma. He has had no progression since chemoradiation in 2024, and he is living a full life.
The aim
Keep the disease stable, have well-reasoned options ready if anything changes, and find what in this tumor points toward a cure.
What analysis can change
Findings go to his treating physicians. He is open to single-patient INDs and compassionate use, and will travel for treatment.
The case
Clinical course: no progression on five concurrent therapies
- Diagnosis
- Astrocytoma, IDH1 R132H, WHO grade 4
- MGMT
- Methylated
- Site
- Right frontotemporal, insular
- Function
- KPS 90, normal exam
- Latest MRI
- 4 Nov 2026, no progression
Bars are continuous treatment; ticks are single doses or sessions; rings are scans. Ivosidenib was held 25 Jul – 12 Aug 2025. Hover any mark for its date.
- Subtotal resection, 28 Dec 2023
- 60 Gy / 30 fractions + temozolomide
- 10 cycles adjuvant temozolomide
- Ivosidenib 500 mg daily
- Optune, ~92–94% wear
- 18-peptide vaccine, 13 doses
- Pembrolizumab 200 mg q3w, 10 infusions
- AutEM RF device (FDA IDE)
- Ketogenic diet
Dataset
Data inventory
All tumor data come from one pre-treatment specimen, the 28 Dec 2023 resection (UCSF S23-42259). Blood and imaging run through Nov 2026.
| Dataset | Specimen | Contents | Format |
|---|---|---|---|
| Exome + RNA, CeGaT | Brain, block B3 | Raw reads; 283 passing somatic calls; gene-level TPM; neoepitope report | FASTQ/BAM · CSV · PDF |
| Exome + RNA, BostonGene | Brain, block B4 | Raw reads; 32 passing somatic calls; expression with percentiles; copy number; PD-L1 IHC | FASTQ/BAM · XLSX · PDF |
| Single-cell RNA, 10x Flex | Brain, FFPE | Count matrices; Loupe file; per-cell labels | MTX/H5 · CLOUPE · CSV |
| UCSF 500 and MGMT | Brain, block B4 | Paired tumor-normal panel report; methylation assay | |
| Germline and HLA | Blood, saliva | CeGaT, Ambry 90-gene, BostonGene | |
| ctDNA | Blood, serial | Northstar Select and Response; Guardant360; Personalis NeXT Personal | |
| Immune monitoring | PBMC, serial | Peptide-pool T-cell response reports | |
| Brain imaging | 17 MRI studies including FET PET-MRI, with reports | DICOM · PDF | |
| Clinical record | Pathology, operative reports, clinical summary, lab history | PDF · CSV |
What the 2023 tissue can and can't tell you
The tumor was sampled once, in Dec 2023, before any treatment. Since then it has had radiation (60 Gy), 10 cycles of temozolomide, ivosidenib, tumor treating fields, a peptide vaccine and pembrolizumab. So treat the tissue data as a baseline, not a picture of the tumor today.
- Germline variants and HLA type
- Founding mutations: IDH1 R132H, TP53 R273C, ATRX
- The IDH1 and TP53 vaccine targets
- Cell-state mix, possibly toward MES-like
- Surface targets such as DLL3, GD2 and SSTR2
- Immune microenvironment, after vaccine and checkpoint therapy
- Mutation load: temozolomide can cause hypermutation; not yet tested
- Blood T-cell responses to the vaccine, through Oct 2026
- Brain MRI, through Nov 2026
If new tissue is ever taken, the 2023 data become the comparison point for how the tumor changed under treatment. Analyses that plan for that comparison now are especially useful.
Open questions
Unresolved findings where analysis could change decisions
Two RNA profiles of the same tumor differ by up to 47-fold
Drug-target genes differ far more than a general glial marker (GFAP) does. Which profile is closer to protein is unknown.
TPM, log scale. Sources: Valius target profile (May 2026); CeGaT raw TPM file.
Copy-number calls differ by tissue block
The two labs that sequenced block B4 agree. The lab that sequenced B3 calls two extra gains. Regional heterogeneity or method is unresolved.
| Call | UCSF 500 B4 | BostonGene B4 | CeGaT B3 |
|---|---|---|---|
| CCND2 amplification, 12p | |||
| EGFR gain, 7p | |||
| CCNE1 gain, 19q |
Filled = called, ring = not called.
Immune-cold tumor, measurable vaccine response in blood
The 2023 tissue has almost no T cells and no PD-L1 protein. Blood T cells now respond to at least 8 of 18 peptides. Whether those T cells reach the tumor is unknown.
DLL3 and GD2: RNA-level targets without protein confirmation
Both are tumor-selective in single-cell RNA. Neither has been confirmed at the protein level, and tissue for stains is limited.
Pericavity T2 change: treatment effect or infiltrative growth
Non-enhancing T2 signal around the cavity has risen slowly since about Dec 2024. Radiology calls it indeterminate. FET PET showed no uptake.
Genomics
Driver alterations are concordant across three labs
Variant allele fraction by lab
IDH1 p.R132H · TP53 p.R273C with 17p copy-neutral LOH · ATRX c.662+2T>C, hemizygous. BostonGene reports no fraction for ATRX.
Genome-wide
- TMB 0.7–1.14 mut/Mb
- Microsatellite stable
- No HRD
- MGMT methylated, 10 of 17 CpG
- CCND2 amp, ~3–4 copies
- Tumor content 66%
- Ki-67 ~15%
Not found
- 1p/19q codeletion
- CDKN2A/B deletion
- TERT promoter
- H3 K27M
- +7/−10
- EGFR mutation
- BRAF/NTRK/RET fusions
Losses (UCSF 500)
- 3
- 8p
- distal 9p
- distal 10q
- 11
- 12q
- distal 21q
Vaccine neoantigens
18 peptides (10 class I, 8 class II) from 11 mutations. CeGaT, Dec 2024.
- IDH1 R132H
- TP53 R273C
- PPP2R2B V293I
- RFC1 A980T
- AGTPBP1 S330T
- MT-ND4 G146S
- ALS2 E76D
- BCL11A R335Q
- CFAP418 K102E
- WNK2 P802A
- NKD1 R288H
HLA and germline
- A*02:01
- A*24:02
- B*18:01
- B*52:01
- C*12:02
- C*12:03
- DRB1*07:01
- DRB1*15:02
- DQB1*02:02
- DQB1*06:01
- DPB1*04:01
Germline: LDLR p.Gly219del (familial hypercholesterolemia). 90-gene hereditary cancer panel negative. UGT1A1 *1/*28.
Pathology
Grade 4 on histology, with no molecular high-grade marker
UCSF surgical pathology S23-42259, resection of 28 Dec 2023. Integrated diagnosis: astrocytoma, IDH-mutant, CNS WHO grade 4.
What makes it grade 4
| Criterion | Present | Finding |
|---|---|---|
| Mitotic activity | Up to 7 per 2 mm² | |
| Microvascular proliferation | Present | |
| Necrosis | Not identified | |
| CDKN2A/B homozygous deletion | Absent (UCSF 500) |
Abundant gemistocytic forms are present (pathology report); UCSF 500 links them to the 12p / CCND2 gain.
Immunohistochemistry
IDH1, p53, Ki-67 and ATRX stained by UCSF pathology on block B3. PD-L1 by BostonGene, 31 Mar 2026.
Microenvironment, bulk RNA estimates
BostonGene, Apr 2026. Cytotoxic genes (GZMB, PRF1, IFNG, CXCL9/10) are at or near zero; HLA class I and TAP1 sit at the 0–1st percentile of astrocytomas.
Tissue remaining
- FFPE blocks B3, B4: limited
- Flash-frozen, held at UCSF
- No living cells
- No organoids or cell lines
- DLL3, SSTR2 stains not done
Everything is from before treatment. The amount of frozen tissue is being confirmed.
Single cell
Composition: 62% tumor, microglia-dominated, 0.3% T and NK cells
Tumor cell states
37,706 tumor cells of 60,575 after doublet removal.
Surface targets by cell type
| Gene | Tumor-selective | Note |
|---|---|---|
| DLL3 | Spread across all tumor states | |
| ST8SIA1, B4GALNT1 | GD2 synthesis; B4GALNT1 mainly NPC/OPC-like | |
| SSTR2 | Very low, mostly AC/MES-like | |
| IL13RA2 | Under 1% of tumor cells | |
| ERBB3 | Also in normal brain cells |
Other tumor-selective candidates: CRB1, MYO16, LRP1B, PCDH15, GRM5. Valius analysis, Jun 2026, investigational.
Immune monitoring
Peptide vaccine T-cell responses
Baseline. One long-peptide pool responds (BCL11A, PPP2R2B, ALS2, MT-ND4).
Strong CD4 response to IDH1 R132H, and to a PPP2R2B / ALS2 / MT-ND4 pool.
IDH1 response persists. CD4 to 7 and CD8 to 2 of 13 pools. Low cell numbers.
First draw after six months of pembrolizumab.
No response to TP53 R273C at any draw. Peptides are tested in pools. Source: CeGaT immune monitoring reports.
Imaging
Seventeen studies, no progression reported
| Date | Study | Radiology read |
|---|---|---|
| 4 Nov 2026 | MRI, 1.5 T | No progression vs Aug. No enhancement, raised perfusion or reduced diffusion |
| 10 Aug 2026 | FET PET-MRI | No FET uptake anywhere in the brain |
| 6 Aug 2026 | Addendum | Indeterminate Pericavity T2 signal up since about Dec 2024 |
| Jun 2024 – May 2026 | 13 MRIs | No progression on each |
| 23 Apr 2024 | MRI | Response to radiation: less infiltrative tumor |
| 26 Jan 2024 | MRI | Residual nodular enhancement at the medial cavity margin |
Second primary: papillary thyroid carcinoma
Found on a surveillance brain MRI in 2024. Genetically distinct from the astrocytoma; no clear recurrence.
- BRAF V600E, 27%
- pT1b(m)N1b, stage I
- 10 of 21 nodes positive
- Thyroidectomy 21 Jan 2025
- No radioactive iodine
- Tumor-informed ctDNA not detected
Access
Data access
Raw and processed files are shared on request with academic and non-profit researchers. Tell us who you are and what you plan to do, and we'll reply by email.
Request data access